Trials / Completed
CompletedNCT04052932
A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
A Phase3, Multicentre, Randomized, Double-Blind, Allopurinol and Placebo-Controlled Study to Evaluate the Efficacy and Safety of SHR4640 Monotherapy in Subjects With Gout
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 594 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to placebo and Allopurinol in patients with gout
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR4640 dose1 | tablets，dose1，QD |
| DRUG | SHR4640 dose2 | tablets，dose2，QD |
| DRUG | Placebo oral tablet | tablets，QD |
| DRUG | Allopurinol 300 MG | tablets，300mg，QD |
Timeline
- Start date
- 2019-07-16
- Primary completion
- 2021-07-14
- Completion
- 2021-07-14
- First posted
- 2019-08-12
- Last updated
- 2022-06-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04052932. Inclusion in this directory is not an endorsement.